Výsledky vyhledávání - "Hepatitis C/*complications/*diagnosis/pathology"

Akademický článek

Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment

Autor: Carine Raquel Blatt, Bernd Storb, Nikolai Mühlberger, Mareni Rocha Farias, Uwe Siebert

Publikováno v: Brazilian Journal of Pharmaceutical Sciences, Vol 50, Iss 2, Pp 345-352 (2014)

Brazilian Guidelines to HCV treatment (2007) recommended that the first choice treatment for patients with chronic hepatitis C (CHC) and genotype 2 or 3 is interferon alpha (IFN) plus ribavirin (RBV) for 24 weeks. The aim of this study is compare the

Externí odkaz: https://doaj.org/article/0749bf695c3643f2ad78bd1dec2ac015

Zobrazit plný text záznamu

HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection

Autor: Enos Bernasconi, Cyril Shah, Pietro Vernazza, Andri Rauch, Dominique L Braun, Jürg Böni, Luisa Salazar-Vizcaya, Sabine Yerly, Huldrych F. Günthard, Roger D. Kouyos, Jan Fehr, Aude Nguyen, Marcel Stoeckle, Teja Turk, Herbert A Mbunkah, Michael Huber, Matthias Cavassini, Karin J. Metzner, Louisa A Carlisle

Publikováno v: Viruses, vol. 12, no. 11, pp. E1241
Viruses, Vol. 12, No 11 (2020) P. 1241
Viruses
Volume 12
Issue 11
Carlisle, Louisa A; Turk, Teja; Metzner, Karin J; Mbunkah, Herbert A; Shah, Cyril; Böni, Jürg; Huber, Michael; Braun, Dominique L; Fehr, Jan; Salazar-Vizcaya, Luisa; Rauch, Andri; Yerly, Sabine; Nguyen, Aude; Cavassini, Matthias; Stoeckle, Marcel; Vernazza, Pietro; Bernasconi, Enos; Günthard, Huldrych F; Kouyos, Roger D (2020). HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. Viruses, 12(11) Molecular Diversity Preservation International MDPI 10.3390/v12111241
Viruses, Vol 12, Iss 1241, p 1241 (2020)

HIV-1 genetic diversity can be used to infer time since infection (TSI) and infection recency. We adapted this approach for HCV and identified genomic regions with informative diversity. We included 72 HCV/HIV-1 coinfected participants of the Swiss H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb46f82db2a2ede9082d5e551bf4a903
https://serval.unil.ch/resource/serval:BIB_D73F11FC1FB6.P001/REF.pdf

Zobrazit plný text záznamu

Blood-borne and sexually transmitted infections: a cross-sectional study in a Swiss prison

Autor: François Girardin, Komal Rachna Chacowry Pala, Laurent Getaz, Hans Wolff, Stéphanie Baggio, Nguyen Toan Tran

Publikováno v: BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Infectious Diseases, Vol. 18, No 1 (2018) P. 539
BMC Infectious Diseases

Background Incarcerated people carry a high burden of infection, including blood-borne diseases (BBDs). It is also known that one million people contract a sexually transmitted infection (STI) every day worldwide, which represents a global public hea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fae4963110ca2249dc9b1af0ff54570
http://link.springer.com/article/10.1186/s12879-018-3445-6

Zobrazit plný text záznamu

Plný text ve formátu HTML

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Autor: Wolfgang Vogel, M. Blachier, Lelia Thornton, Wim Laleman, Ieva Tolmane, Antonio Craxì, Mojca Matičič, Hans Van Vlierberghe, Christoph Sarrazin, Laura Harcouet, Joël Mossong, Ilias Gountas, Matthew E. Cramp, Devin Razavi-Shearer, Soo Aleman, Lyudmila Mateva, Ann-Sofi Duberg, Vratislav Nemecek, Jordan Genov, Michael Manns, Anne Øvrehus, Irena Hrstić, Kimberly Murphy, Stefano Vella, Krzysztof Tomasiewicz, Francesco Negro, Nina Weis, Antonio Javier Blasco, Agita Jeruma, Karolin Falconer, Danute Speiciene, Jonas Valantinas, Jose Luis Calleja, Jan Sperl, Gabor Horvath, Filipe Calinas, Peter Jarcuska, Jerneja Videčnik-Zorman, Ivan Schréter, Kathryn Razavi-Shearer, Christophe Moreno, Sergeja Gregorčič, Angelos Hatzakis, Pierre Van Damme, Riina Salupere, Massimo Colombo, Robert J. de Knegt, Peter J Smit, Dijana Nonkovic, Daniela K van Santen, Waldemar Halota, Rui Sarmento-Castro, Jean-Michel Delile, Suzanne Norris, Vana Sypsa, Robert Flisiak, Carole Seguin-Devaux, Martin Lagging, Liana Gheorghe, Mihály Makara, Javier García-Samaniego, Christophe Hézode, Jennifer Kieran, Marian Oltman, Peter Stärkel, Victor de Ledinghen, Pablo Lázaro, Stefan Zeuzem, E. A. Croes, Patrick Hoffmann, Matti Maimets, Francesco Saverio Mennini, Kostas Athanasakis, Chris Estes, Stephen D. Ryder, Sarah Robbins, Françoise Roudot-Thoraval, Martin Kåberg, Kaarlo Simojoki, Sona Frankova, Adrian Goldis, Marietta Simonova, Kyriakos Souliotis, Ken Pasini, Homie Razavi, Rui Tato Marinho, Sarah Blach, Pavol Kristian, Rumiana Mitova, Loreta A. Kondili, Maria Buti, Helen Nde, Boris Lukšić, Henrik Krarup, Dominique Vandijck, Henk W. Reesink, David A. M. C. van de Vijver, Iskren Kotzev, Jessie Gunter, Adriaan J. van der Meer, Martti Färkkilä, Baiba Rozentale, Perttu Arkkila, Krasimir Antonov, Jan Gerstoft, Béla Hunyady, Peer Brehm Christensen, Ivane Gamkrelidze, Valentina Liakina, Michael Gschwantler, Deian Jelev, Tatjana Reic, George V. Papatheodoridis, Jonathan Schmelzer, Daniel Struck

Publikováno v: Krarup, H & European Union HCV Collaborators 2017, ' Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030 : a modelling study ', The Lancet Gastroenterology & Hepatology, vol. 2, no. 5, pp. 325-336 . https://doi.org/10.1016/S2468-1253(17)30045-6
Lancet Gastroenterology & Hepatology, 2(5), 325-336. Elsevier Ltd.
The Lancet Gastroenterology & Hepatology, Vol. 2, No 5 (2017) pp. 325-336
Lancet gastroenterology & hepatology
The lancet. Gastroenterology & hepatology, 2(5), 325-336. HANLEY & BELFUS-ELSEVIER INC
Øvrehus, A L H & European Union HCV Collaborators 2017, ' Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030 : a modelling study ', The Lancet Gastroenterology & Hepatology, vol. 2, no. 5, pp. 325-336 . https://doi.org/10.1016/S2468-1253(17)30045-6

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% red

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6167fe45cfcadfaa8e9dc89df3a54984
https://doi.org/10.1016/s2468-1253(17)30045-6

Zobrazit plný text záznamu

The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses

Autor: Eloi R. Verrier, Carla Eller, Thomas F. Baumert, Catherine Schuster, Laura Heydmann, Che C. Colpitts

Publikováno v: Cellular and Molecular Life Sciences Cmls
Cellular and Molecular Life Sciences Cmls, 2018, 75 (21), pp.3895-3905. ⟨10.1007/s00018-018-2892-y⟩
Cell Mol Life Sci
Cellular and Molecular Life Sciences

Chronic hepatitis B, C and D virus (HBV, HCV and HDV) infections are a major cause of liver disease and cancer worldwide. Despite employing distinct replication strategies, the three viruses are exclusively hepatotropic, and therefore depend on hepat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c067d8c5a7ff91c28aa72a1f16a5694
https://hal.archives-ouvertes.fr/hal-02374180/document

Zobrazit plný text záznamu

EASL Recommendations on Treatment of Hepatitis C 2018

Autor: Jean-Michel Pawlotsky, Francesco Negro, Alessio Aghemo, Marina Berenguer, Olav Dalgard, Geoffrey Dusheiko, Fiona Marra, Massimo Puoti, Heiner Wedemeyer

Publikováno v: Journal of Hepatology, Vol. 69, No 2 (2018) pp. 461-511

Summary Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5217e865a9068b424cd86b0fa77cca01
https://archive-ouverte.unige.ch/unige:125796

Zobrazit plný text záznamu

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

Publikováno v: Alimentary Pharmacology and Therapeutics
Alimentary Pharmacology and Therapeutics, 2017, 46 (11-12), pp.1054--1060. ⟨10.1111/apt.14352⟩
Alimentary Pharmacology and Therapeutics, Wiley, 2017, 46 (11-12), pp.1054--1060. ⟨10.1111/apt.14352⟩
Alimentary Pharmacology and Therapeutics, Vol. 46, No 11-12 (2017) pp. 1054-1060

International audience; BACKGROUND: Hepatitis B virus (HBV)/hepatitis C virus (HCV) confection has been rarely studied in nonasian series. AIM: To compare the characteristics of HBV/HCV coinfected patients to those of HBV- or HCV-monoinfected patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2447c53c607ea3f7ca805941e5c4a1fb
https://hal.science/hal-01743648

Zobrazit plný text záznamu

Akademický článek

SERUM CONCENTRATIONS OF sIL-2R, IL-6, TGF-β1, NEOPTERIN, AND ZINC IN CHRONIC HEPATITIS C PATIENTS TREATED WITH INTERFERON-ALPHA

Autor: Grüngreiff, K ^{a, f1f1Correspondence to: Kurt Grüngreiff, Heydeckstr. 9, D-39104 Magdeburg, Germany}, Reinhold, D ^a, Ansorge, S ^b

Publikováno v: In Cytokine December 1999 11(12):1076-1080

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání